A fast-growing East Bay company crossing the boundaries of biotech, manufacturing, chemicals and agriculture landed a $400 million investment that hints at a potential public offering.
Zymergen Inc., which has raised a total of $574 million since it was formed five years ago, said the Series C round was led by returning investor SoftBank Vision Fund. The round included new investors Goldman Sachs and Hanwha Asset Management as well as returning investors Data Collective, True Ventures, Two Sigma…
